Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

摘要: Selective small-molecule kinase inhibitors have emerged over the past decade as an important class of anti-cancer agents, and demonstrated impressive clinical efficacy in several different diseases, including relatively common malignancies such breast lung cancer. However, benefit is typically limited to a fraction treated patients. Genomic features individual tumours contribute significantly responses, these seem vary tremendously across Additional factors, pharmacogenomics, tumour microenvironment rapidly acquired drug resistance, also sensitivity various cancers, should be considered applied development use new inhibitors.